Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute. Learn more about Cancer Currents.
-
Sodium Thiosulfate Approved to Reduce Chemo-Related Hearing Loss in Children with CancerThe chemotherapy cisplatin often causes permanent hearing loss. Sodium thiosulfate (Pedmark) is the first treatment approved by FDA that can reduce the risk of hearing loss and the severity of damage to the inner ear in children treated with cisplatin.
-
Teclistamab Shows Promise for People with Heavily Pretreated Multiple MyelomaIn a small clinical trial, nearly 40% of people with multiple myeloma who were treated with the immunotherapy drug teclistamab (Tecvayli) had all signs of their cancer disappear. The trial participants had myeloma that did not respond to or came back after three or more prior treatments.
-
Making Transformative Advances against Childhood Cancer: A Conversation with Dr. Doug HawkinsDr. Doug Hawkins, chair of the NCI-funded Children’s Oncology Group, discusses advances in treating children with cancer, COG’s role in conducting clinical trials, and efforts like the Childhood Cancer Data Initiative and Molecular Characterization Initiative.
-
Vulnerability in Brain Tumors May Open Door to New TreatmentsTwo companion studies have found different forms of some brain tumors, diffuse midline glioma and IDH-mutant glioma, become dependent for their survival on the production of chemicals called pyrimidines. Clinical trials are planned to test a drug that blocks pyrimidine synthesis in patients with gliomas.
-
New on NCI’s Websites for September 2022NCI periodically provides updates on new websites and other online content of interest to the cancer community. See selected content that has been added as of September 2022.
-
Enhertu Marks First Targeted Therapy for HER2-Mutant Lung CancerOn August 11, the Food and Drug Administration (FDA) gave accelerated approval to trastuzumab deruxtecan (Enhertu) for adults with non-small cell lung cancer (NSCLC) that has a specific mutation in the HER2 gene. Around 3% of people with NSCLC have this kind of HER2 mutation.
-
Study Confirms Dinutuximab Extends Life for Children with High-Risk NeuroblastomaResearchers have confirmed that the immunotherapy drug dinutuximab (Unituxin) can help children with high-risk neuroblastoma live longer. The finding is based on a trial of nearly 1,200 children with the disease.
-
For Common Form of Bladder Cancer, Chemo Combo Effective Alternative to BCGThe standard treatment for high-risk non-muscle-invasive bladder cancer (NMIBC), a drug called BCG, has been in shortage for a decade. Bladder cancer experts agree that gemcitabine and docetaxel offers an effective alternative to BCG, after a study showed that 82% of patients with high-risk NMIBC treated with the combination were alive 2 years later without their cancer returning.
-
Study Tackles Key Questions about Liver Transplants for People with Liver CancerFor some people with hepatocellular carcinoma (HCC), the most common type of liver cancer, a liver transplant is the only hope for a cure. A new study shows a high 10-year survival rate for people who got a liver transplant after their tumors were “downstaged” to become eligible for a transplant.
-
Abnormal Collagen May Be Weak Spot for Pancreatic CancerAbnormal collagen that is formed only by pancreatic cancer cells ramps up activity that increases tumor growth and survival, a study found. In mice, blocking production or effects of the abnormal collagen made treatment for pancreatic cancer more effective.
-
Targeting Inflammation Emerges as a Strategy for Treating CancerInflammation is considered a hallmark of cancer. Researchers hope to learn more about whether people with cancer might benefit from treatments that target inflammation around tumors. Some early studies have yielded promising results and more are on the horizon.
-
Pembrolizumab Improves Survival in Advanced Triple-Negative Breast CancerAdding the immunotherapy drug pembrolizumab (Keytruda) to chemotherapy can help some patients with advanced triple-negative breast cancer live longer. In the KEYNOTE-355 trial, overall survival improved among patients whose tumors had high levels of the PD-L1 protein.
-
Targeting the Accomplice: A Potential Treatment Approach for RhabdomyosarcomaThe fusion protein that drives the growth and survival of some rhabdomyosarcoma tumors relies on the KDM4B enzyme, researchers have found. Treating mice with a KDM4B-blocking drug and chemotherapy nearly eliminated rhabdomyosarcoma tumors with the fusion protein.
-
Aided by Community Health Workers, People with Advanced Cancer Need Fewer Hospital VisitsRegular visits and calls from community health workers showed many benefits for those with advanced cancers, from greater use of palliative care to improved quality of life, a new study has shown.
-
New Cancer Model Shows Promise in Predicting If Treatment Will Shrink TumorsA research team hopes to offer oncologists a new tool to guide treatment choices for their patients. In a small study, a tumor model called micro-organospheres accurately predicted whether patients would respond to their chemotherapy treatment.
-
Disguising Cancer as an Infection Helps the Immune System Eliminate TumorsNCI researchers are developing an immunotherapy that involves injecting protein bits from cytomegalovirus (CMV) into tumors. The proteins coat the tumor, causing immune cells to attack. In mice, the treatment shrank tumors and kept them from returning.
-
Dabrafenib–Trametinib Combination Approved for Solid Tumors with BRAF MutationsFDA has approved the combination of the targeted drugs dabrafenib (Tafinlar) and trametinib (Mekinist) for nearly any type of advanced solid tumor with a specific mutation in the BRAF gene. Data from the NCI-MATCH trial informed the approval.
-
Androgen Receptor May Explain Sex Differences in Melanoma Treatment ResponseMale patients with metastatic melanoma don’t live as long as females, and their tumors are more likely to become resistant to commonly used treatments. A new study may help explain why: the androgen receptor.
-
Immunotherapy’s Skin Side Effects: Are Microbes to Blame?People with cancer who take immunotherapy drugs often develop skin side effects, including itching and painful rashes. New research in mice suggests these side effects may be caused by the immune system attacking new bacterial colonies on the skin.
-
Ifosfamide May Be Treatment of Choice for Some People with Ewing Sarcoma, Trial ShowsNew findings from the first large, randomized clinical trial to compare chemotherapy regimens for relapsed or treatment-resistant Ewing sarcoma could help doctors and patients select treatments.